3 - PUVA, NB-UVB and UVA-1 phototherapy Flashcards
UVA wavelength is 320-400nm
True
UVB wavelength is 311nm
True
Psoralen plus ultraviolet A (PUVA) photochemotherapy is the photochemical interaction between a psoralen medication and UVA radiation
True
Psoralens are naturally occurring compounds acting as natural insecticides
True
Human contact with plants containing psoralens and subsequent exposure to sunlight results in phytophotodermatitis
True
Phytophotodermatitis represents an acute phototoxic reaction in the skin manifested as erythema, blistering and pigmentation
True
The presence of psoralen in the skin before and after exposure can be harmful through unintentional exposure to sunlight resulting in undesirable phototoxicity
True
Psoralens are lipophilic and poorly soluble in water
True
There are 2 types of psoralens available, namely 8-MOP (methoxsalen) and 5-MOP (bergapten) where 8-MOP is more water soluble than 5-MOP
True
The water solubility of psoralens determines the bioavailability of these compounds
True
8-MOP (Methoxsalen) is available as 2 formulations of dissolved psoralen (Oxsoralen Ultra) and micronised crystals of 8-MOP
True
Dissolved psoralen (Oxsoralen Ultra) is rapidly and more completely absorbed as compared to the 8-MOP micronised crystals
True (accounts for dissolved psoralen being dosed at 0.4mg/kg and taken 1 hour prior to UVA and micronised crystals 8-MOP being dosed at 0.6mg/kg and 2 hours prior to UVA)
High fat foods can slow down the absorption of psoralens
True (psoralens is ideally taken under fasting conditions although food intake can be used to alleviate the nausea associated with high serum level of the drug)
Nausea is associated with high serum levels of psoralen
True (food intake with the drug can alleviate this adverse effect)
Psoralens exhibit first pass metabolism in the liver and intestines
True (therefore doses <20mg may not be clinically effective)
Psoralens highly bind to serum albumin
True
8-MOP (Methoxsalen) is more photoactive than 5-MOP (Bergapten)
True
The physical formulation of psoralen influences its absorption
True (8-MOP dissolved psoralen more readily absorbed than 8-MOP micronised crystals)
Methoxsalen (8-MOP) is completely metabolised in the liver through the CYP 450 system
True
Cytochrome P450 inducers have an effect on the metabolism of psoralens
True (cytochrome P450 inducers enhance and accelerate the metabolism of 8-MOP therefore reducing the biological effect of PUVA)
Most of 8-MOP is excreted in the kidneys
True
The peak of the absorption spectrum for psoralen molecules to be activated to the excited singlet state is in the region of 320-330nm
True
PUVA therapy suppresses DNA synthesis through the formation of monoadducts and cross links in the DNA
True
PUVA therapy causes selective immunosuppression
True
NB-UVB phototherapy is almost as effective as PUVA for psoriasis not involving the palms and soles
True
NB-UVB has replaced PUVA as the treatment of choice for vitiligo as both treatments have comparable efficacy but NB-UVB is simpler
True
Vitiligo on the face and torso are more responsive to phototherapy than on the limbs
True
The eczematous and plaque stages of mycosis fungoides respond to PUVA
True
The tumour stage of mycosis fungoides does not usually respond to PUVA
True (PUVA is usually not effective in the tumour phase of the disease)
Sezary syndrome is not responsive to PUVA
True
Patients with various photodermatoses can be desensitised by prophylactic exposure to a brief course of PUVA
True
Pemphigoid is contraindicated in PUVA and NB-UVB
True
Pemphigus is contraindicated in PUVA and NB-UVB
True
Lactation is contraindicated in PUVA
True (because psoralens is probably secreted in breast milk)
Lupus erythematosus with photosensitivity is contraindicated in PUVA and NB-UVB
True
Xeroderma pigmentosum is contraindicated in PUVA and NB-UVB
True
A 25% reduction in PUVA dose should be considered in patients taking photosensitising agents
True
PUVA dose should be readjusted when patient is concurrently on doxycycline
True (photosensitising agent)
PUVA dose should be readjusted when patient is concurrently on fluoroquinolones
True (lomefloxacin and sparfloxacin are photosensitising agents)
The PUVA radiation dose is dependant on skin phototype
True
If widespread erythema is present post PUVA, treatment should be stopped until the erythema clears
True
When >95% of the psoriasis area has cleared post PUVA, the patient is stepped down to a maintenance schedule of PUVA
True
If a significant (>5%) amount of psoriasis begins to return then the frequency of PUVA can be increased or stepped up to a clearance schedule
True
Areas shielded from PUVA therapy should be concurrently managed with topical corticosteroid therapy
True
Eye protection with UVA blocking glasses is required for PUVA therapy
True (required from time of psoralen ingestion until sunset that day when the patient is exposed to sunlight)
A sunscreen with at least SPF 15 ideally includes avobenzone as an ingredient is advised for photoprotection from psoralen phototoxic reaction
True
Nausea correlates with the serum level of psoralen
True (most common adverse effect)
The PUVA itch (pruritus) and subacute phototoxicity are indications for stopping treatment until they clear
True
Symptomatic erythema is the most common phototoxic reaction
True (10% of patients)
PUVA may cause CNS disturbances
True
PUVA may cause depression
True
PUVA may cause headaches
True
PUVA may cause hyperactivity
True
PUVA lentigines is an association of PUVA treatment
True
NMSC incidence is markedly increased in patients who receive high cumulative UVA exposure
True (dose dependant)
The SCC is PUVA patients are not biologically more aggressive than actinically induced SCCs in immunocompetent patients
True
There is an increased risk of SCC on male genitalia with PUVA treatment
True
PUVA may cause herpes simplex virus recurrences
True
There is no increased incidence of cataracts with PUVA
True
Thiazides diuretics do not cause acute phototoxic erythema with PUVA
True (though a potentially photoactive agent, thiazides diuretics do not cause phototoxicity with PUVA)
Carbamazepine may reduce the effectiveness of PUVA
True (carbamazepine is a CYP 450 enzyme inducer and enhances the metabolism of psoralen)
Phenytoin may reduce the effectiveness of PUVA
True (phenytoin is a CYP 450 enzyme inducer and enhances the metabolism of psoralen)
Other CYP 450 inducers may reduce the effectiveness of PUVA
True (enhance the metabolism of psoralen)
Skin cancer is the most important adverse effect of long term PUVA treatment
True (need for long term skin checks even after cessation of PUVA)
The peak of the action spectrum for phototherapy of psoriasis is in the 320-340nm spectrum
True
UVB is absorbed in the epidermis and papillary dermis
True
UVA wavelengths generally penetrate to the mid dermis
True
Topical emollients are advised before NB-UVB to make lesions more transparent
True
Bullae may appear on psoriatic plaques after NB-UVB phototherapy
True
Lupus erythematosus may be a consequence of NB-UVB treatment
True
Pemphigus may be a consequence of NB-UVB treatment
True
Pemphigoid may be a consequence of NB-UVB treatment
True
Recurrent herpes labialis may be an adverse effect of NB-UVB treatment
True
Polymorphous light eruption can be an adverse effect of NB-UVB treatment
True
UVA-1 wavelength is 340-400nm
True
UVA-1 treatment is equivalent to NB-UVB and UVA treatment
True (no clear advantage of UVA-1)
UVA-1 produces DNA damage in vivo and in vitro
True
Erythema is the main short term effect of UVA-1 phototherapy
True
Erythema from UVA-1 phototherapy is usually asymptomatic
True (usually asymptomatic and does not interfere with treatment)